Annovis Bio Inc (ANVS)

$3.65 +0.19 (5.49%)
Market Cap 96.74M
Revenue (ttm) 0.00
Net Income (ttm) -24.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 469,600
Avg Vol 1,889,846
Day's Range N/A - N/A
Shares Out 26.50M
Stochastic %K 50%
Beta 1.46
Analysts Strong Sell
Price Target $11.67

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
Veni_Vidi_Vici
Veni_Vidi_Vici Jan. 5 at 3:59 AM
$ANVS https://clinicaltrials.gov/study/NCT07284784?cond=Buntanetap&rank=1
0 · Reply
Trills
Trills Jan. 5 at 3:09 AM
$ANVS "Rather than there being one type of Alzheimer’s, there are actually multiple that each require different treatment approaches." abridged article: https://www.zerohedge.com/medical/reversing-alzheimers-forgotten-causes-and-cures-big-pharma-buried from a longer article which discusses the causes and treatments for Alzheimer’s disease and the cognitive decline which precedes it. https://www.midwesterndoctor.com/p/the-great-alzheimers-scam-and-the
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 4 at 4:53 AM
Enter: $ANVS Calls Strike Price: $4 Expiry Date: JAN 30 2026 Buy in Price: $0.50 - $4.90 Sell Price: $0.88 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 4:16 AM
Enter: $ANVS Calls Strike Price: $4 Expiry Date: JAN 23 2026 Buy in Price: $2.79 - $4.90 Sell Price: $6.33 Profit : +127% (Turn every $1 into $2.27) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
BIOMILITIA
BIOMILITIA Jan. 2 at 11:48 PM
$ANVS Simallar close for alot of bios i watch.
0 · Reply
5xStarTrader
5xStarTrader Jan. 2 at 9:50 PM
$ANVS Shows you that the only sellers (mainly the market makers), today were the short sellers who couldn’t create a sell off allowing them to cover at lower prices and wound up getting spooked into a scramble buying back their own short positions while the real investors kept buying more cheap shares.
0 · Reply
MomoMrCow
MomoMrCow Jan. 2 at 9:21 PM
$ANVS interesting price action today 👀 especially towards the close
0 · Reply
To_De_Moon
To_De_Moon Jan. 2 at 8:58 PM
$ANVS this should finnally be THE YEAR 🤞❤️
1 · Reply
Tubular9988
Tubular9988 Jan. 2 at 3:35 PM
$ANVS these are a series of low volume pullbacks around the dead xmas season, before the big 2026 ramp up. nothing to worry about. ANVS stock should base around 3.3.
0 · Reply
Fraser100
Fraser100 Jan. 2 at 2:31 PM
$ANVS so that would make you “extremely bullish” while the general sentiment is “extremely bearish” . What do you base your sentiment on? Obviously the market is aware of the ph 3 results approaching as well. Just an honest question.
2 · Reply
Latest News on ANVS
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 18, 2025, 4:35 PM EST - 17 days ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 16, 2025, 8:00 AM EST - 19 days ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Dec 3, 2025, 8:00 AM EST - 4 weeks ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 24, 2025, 8:00 AM EST - 5 weeks ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Nov 18, 2025, 8:00 AM EST - 6 weeks ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Nov 17, 2025, 1:07 PM EST - 6 weeks ago

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 17, 2025, 8:00 AM EST - 6 weeks ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 7 weeks ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Nov 6, 2025, 8:00 AM EST - 2 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 27, 2025, 8:00 AM EDT - 2 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 15, 2025, 5:15 PM EDT - 2 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 3 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Oct 9, 2025, 7:30 AM EDT - 3 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 3 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 16, 2025, 7:30 AM EDT - 3 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 5 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 26, 2025, 8:00 AM EDT - 6 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 19, 2025, 6:30 AM EDT - 7 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 7 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:30 PM EDT - 8 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 8 months ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 27, 2025, 4:30 PM EDT - 10 months ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 25, 2025, 8:00 AM EDT - 10 months ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 21, 2025, 5:05 PM EDT - 10 months ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Mar 11, 2025, 8:00 AM EDT - 10 months ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 11 months ago

Annovis to Host Patients' Live Forum on February 27, 2025

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 7, 2025, 8:00 AM EST - 11 months ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 5, 2025, 8:00 AM EST - 11 months ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 4, 2025, 4:31 PM EST - 11 months ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Jan 14, 2025, 8:00 AM EST - 1 year ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

/C O R R E C T I O N -- Today's Marketplace/

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/

Annovis to Host Year-End Investor Webcast on December 11, 2024

Nov 25, 2024, 8:00 AM EST - 1 year ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Oct 31, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Oct 15, 2024, 8:00 AM EDT - 1 year ago

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Oct 3, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Jul 24, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 4:13 PM EDT - 1 year ago

Annovis stock more than doubled on Tuesday: what happened?

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Jul 2, 2024, 1:57 PM EDT - 1 year ago

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Jun 26, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Jun 11, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Annovis Announces New Publication in a Peer-Reviewed Journal

May 21, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces New Publication in a Peer-Reviewed Journal

Veni_Vidi_Vici
Veni_Vidi_Vici Jan. 5 at 3:59 AM
$ANVS https://clinicaltrials.gov/study/NCT07284784?cond=Buntanetap&rank=1
0 · Reply
Trills
Trills Jan. 5 at 3:09 AM
$ANVS "Rather than there being one type of Alzheimer’s, there are actually multiple that each require different treatment approaches." abridged article: https://www.zerohedge.com/medical/reversing-alzheimers-forgotten-causes-and-cures-big-pharma-buried from a longer article which discusses the causes and treatments for Alzheimer’s disease and the cognitive decline which precedes it. https://www.midwesterndoctor.com/p/the-great-alzheimers-scam-and-the
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 4 at 4:53 AM
Enter: $ANVS Calls Strike Price: $4 Expiry Date: JAN 30 2026 Buy in Price: $0.50 - $4.90 Sell Price: $0.88 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 4:16 AM
Enter: $ANVS Calls Strike Price: $4 Expiry Date: JAN 23 2026 Buy in Price: $2.79 - $4.90 Sell Price: $6.33 Profit : +127% (Turn every $1 into $2.27) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
BIOMILITIA
BIOMILITIA Jan. 2 at 11:48 PM
$ANVS Simallar close for alot of bios i watch.
0 · Reply
5xStarTrader
5xStarTrader Jan. 2 at 9:50 PM
$ANVS Shows you that the only sellers (mainly the market makers), today were the short sellers who couldn’t create a sell off allowing them to cover at lower prices and wound up getting spooked into a scramble buying back their own short positions while the real investors kept buying more cheap shares.
0 · Reply
MomoMrCow
MomoMrCow Jan. 2 at 9:21 PM
$ANVS interesting price action today 👀 especially towards the close
0 · Reply
To_De_Moon
To_De_Moon Jan. 2 at 8:58 PM
$ANVS this should finnally be THE YEAR 🤞❤️
1 · Reply
Tubular9988
Tubular9988 Jan. 2 at 3:35 PM
$ANVS these are a series of low volume pullbacks around the dead xmas season, before the big 2026 ramp up. nothing to worry about. ANVS stock should base around 3.3.
0 · Reply
Fraser100
Fraser100 Jan. 2 at 2:31 PM
$ANVS so that would make you “extremely bullish” while the general sentiment is “extremely bearish” . What do you base your sentiment on? Obviously the market is aware of the ph 3 results approaching as well. Just an honest question.
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 1 at 11:07 PM
Enter: $ANVS Calls Strike Price: $4 Expiry Date: JAN 23 2026 Buy in Price: $0.55 - $2.79 Sell Price: $5.27 Profit : +89% (Turn every $1 into $1.89) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
1 · Reply
Tubular9988
Tubular9988 Jan. 1 at 12:23 PM
$ANVS i believe that 2026 is going to be an amazing year for ANVS. multi-bagger in the making. wall street will re-rate and revalue higher throughout year as ph 3 results approach in Fall, particularly as this is for Alzheimers.
1 · Reply
Juhanialainen
Juhanialainen Jan. 1 at 2:18 AM
$SLS I know I’m not a great follow-upper. Don’t need to be. Not a doctor. But ever since I gave $SAVA and $ANVS headsups to some people I gathered some people around to listen up what I have to say. Thank you for doing so. Thank you. This is the beginning.
1 · Reply
Sulmona39
Sulmona39 Jan. 1 at 1:44 AM
$ANVS $AXSM they completed phase lll for Alzymers decease AGITATION !
0 · Reply
Hockeyfanatic
Hockeyfanatic Jan. 1 at 1:00 AM
$ANVS $ANVS what phase was $AXSM when they recieved fast tracked approval? how does it compare on where $ANVS currently is?
0 · Reply
Madsj79
Madsj79 Dec. 31 at 1:33 PM
$ANVS $AXSM announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 31 at 5:52 AM
Enter: $ANVS Calls Strike Price: $4 Expiry Date: JAN 23 2026 Buy in Price: $0.70 - $2.79 Sell Price: $5.89 Profit : +111% (Turn every $1 into $2.11) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Tubular9988
Tubular9988 Dec. 30 at 4:27 PM
$ANVS anvs could be a real runner in January 2026 and revalued higher.
0 · Reply
Madsj79
Madsj79 Dec. 30 at 9:50 AM
$ANVS https://www.cell.com/cell/fulltext/S0092-8674(25)01368-6
2 · Reply
rsheth76
rsheth76 Dec. 30 at 5:36 AM
$ANVS https://www.nasdaq.com/press-release/annovis-host-corporate-update-webinar-january-28-2026-2025-12-16
0 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Dec. 29 at 12:46 PM
$ANVS I am no expert. Do your own due diligence. Understand the risks before investing in a clinical stage biotech. Annovis Followers on Stocktwits = 9,703
1 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Dec. 29 at 12:34 PM
$ANVS https://drive.google.com/file/d/1NeSyFA37b9IbUzryRRP-EqrgScjCRL-3/view?pli=1
1 · Reply